Table 1. Studies of anti–PD-1 antibody... | American Society of Hematology

Table 1.

Studies of anti–PD-1 antibody monotherapy in rel/ref HL

Study	Phase	N	BV failure, %	ASCT failure, %	ORR	CR	PFS	OS
Nivolumab	1	23	78	78	87	17	86% at 24 wk	NR
Nivolumab
Overall		243	74	100	69	16	14.7 mo	92% at 1 y
Cohort A	2	63	0	100	65	29	18.3 mo	93% at 1 y
Cohort B		80	100	100	68	13	14.7 mo	93% at 1 y
Cohort C		100	100	100	73	12	11.9 mo	90% at 1 y
Pembrolizumab	1	31	100	71	65	16	46% at 52 wk	100% at 24 wk
Pembrolizumab
Overall		210	71	61	69	22	63% at 9 mo	98% at 9 mo
Cohort 1	2	69	100	100	74	22
Cohort 2		81	100	0	64	25
Cohort 3		60	0	100	70	20

Study	Phase	N	BV failure, %	ASCT failure, %	ORR	CR	PFS	OS
Nivolumab	1	23	78	78	87	17	86% at 24 wk	NR
Nivolumab
Overall		243	74	100	69	16	14.7 mo	92% at 1 y
Cohort A	2	63	0	100	65	29	18.3 mo	93% at 1 y
Cohort B		80	100	100	68	13	14.7 mo	93% at 1 y
Cohort C		100	100	100	73	12	11.9 mo	90% at 1 y
Pembrolizumab	1	31	100	71	65	16	46% at 52 wk	100% at 24 wk
Pembrolizumab
Overall		210	71	61	69	22	63% at 9 mo	98% at 9 mo
Cohort 1	2	69	100	100	74	22
Cohort 2		81	100	0	64	25
Cohort 3		60	0	100	70	20

NR, not reached.